Xolair Enhances Oral Desensitization in Peanut Allergic Patients
NCT01290913
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
13
Enrollment
OTHER
Sponsor class
Conditions
Peanut Allergy
Interventions
DRUG:
Omalizumab
Sponsor
Lynda Schneider